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Abstract
 
Infection of inbred mouse strains with 
 
Leishmania major
 
 is a well characterized model for analy-
sis of T helper (Th)1 and Th2 cell development in vivo. In this study, to address the role of co-
stimulatory molecules CD27, CD30, 4-1BB, and OX40, which belong to the tumor necrosis
factor receptor superfamily, in the development of Th1 and Th2 cells in vivo, we administered
 
monoclonal antibody (mAb) against their ligands, CD70, CD30 ligand (L), 4-1BBL, and OX40L,
to mice infected with 
 
L
 
.
 
 major
 
. Whereas anti-CD70, anti-CD30L, and anti–4-1BBL mAb ex-
hibited no effect in either susceptible BALB/c or resistant C57BL/6 mice, the administration
of anti-OX40L mAb abrogated progressive disease in BALB/c mice. Flow cytometric analysis
 
indicated that OX40 was expressed on CD4
 
1
 
 T cells and OX40L was expressed on CD11c
 
1
 
dendritic cells in the popliteal lymph nodes of 
 
L
 
.
 
 major
 
–infected BALB/c mice. In vitro stimu-
lation of these CD4
 
1
 
 T cells showed that anti-OX40L mAb treatment resulted in substantially
reduced production of Th2 cytokines. Moreover, this change in cytokine levels was associated
with reduced levels of anti–
 
L
 
.
 
 major
 
 immunoglobulin (Ig)G1 and serum IgE. These results indi-
cate that anti-OX40L mAb abrogated progressive leishmaniasis in BALB/c mice by suppressing
the development of Th2 responses, substantiating a critical role of OX40–OX40L interaction
in Th2 development in vivo.
Key words: OX40/OX40 ligand • experimental leishmaniasis • Th1/Th2 differentiation • 
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Introduction
 
Two functionally distinct CD4
 
1
 
 T cell subsets, designated
Th1 and Th2, have been implicated in differential host re-
 
sponses to infectious diseases. Th1 cells produce IFN-
 
g
 
 and
IL-2 and promote cellular immune responses and inflamma-
tory reactions. Th2 cells produce IL-4, IL-5, and IL-6 and
promote humoral immune responses and allergic reactions.
Some cytokines play a definitive role in the development
of Th1 and Th2; IL-12 induces Th1, whereas IL-4 induces
Th2 (1). In addition to these cytokines, the development of
Th1 and Th2 appears to be influenced by costimulatory
molecules expressed on APCs. It has been shown that CD80
and CD86, two ligands for CD28 on T cells, may differen-
tially regulate Th1 and Th2 development (2). Some mem-
 
bers of the TNFR superfamily, including CD27, CD30,
4-1BB, and OX40, have been shown to transmit a costim-
ulatory signal for T cell proliferation and cytokine produc-
tion like CD28 (3, 4). CD27 has been reported to enhance
 
IL-2 production by human CD4
 
1
 
 T cells (5). CD30 is pref-
erentially expressed on Th2 cells and reported to promote
Th2 development in vitro (6). 4-1BB has been reported to
promote Th1 cell responses by enhancing IL-2 and IFN-
 
g
 
production but suppressing IL-4 production (7). Moreover,
it has been reported that OX40 costimulation promoted
the differentiation of naive CD4
 
1
 
 T cells into Th2 cells
producing IL-4 in vitro (8, 9). These in vitro observations
raise the possibility that these costimulatory molecules may
be involved in the development of Th1 and Th2 in vivo.
 
Experimental infection with the intracellular parasite 
 
Leish-
mania major
 
 is a well characterized model for analysis of Th1
and Th2 development in vivo (10). C57BL/6 mice are re-
sistant to 
 
L
 
.
 
 major
 
 infection in association with develop-
ment of Th1 cells that produce IFN-
 
g
 
. The critical role of
IFN-
 
g
 
 in controlling 
 
L
 
.
 
 major
 
 infection has been established
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by results showing that genetically resistant mice with dis-
rupted IFN-
 
g
 
 or IFN-
 
g
 
R genes failed to resolve the lesions
(11, 12). In contrast, susceptible BALB/c mice develop pro-
gressive lesions in association with development of Th2 cells
that produce IL-4. Studies using neutralizing anti–IL-4 an-
tibodies or mice with a disrupted IL-4 gene have defined a
critical role of IL-4 in mediating the differentiation of Th2
in vivo and the failure to control 
 
L
 
.
 
 major
 
 infection (13, 14).
Using this well characterized system, we address the role of
CD27, CD30, 4-1BB, and OX40 costimulation in Th1
and Th2 development in vivo by administrating blocking
antibodies against their ligand to 
 
L
 
.
 
 major
 
–infected C57BL/6
or BALB/c mice. Notably, anti-OX40L mAb abrogated
progressive disease in susceptible BALB/c mice in associa-
tion with reduced production of Th2 cytokines by draining
LN T cells and reduced levels of anti–
 
L
 
. 
 
major
 
 IgG1 and se-
rum IgE. We found OX40 expression on CD4
 
1
 
 T cells
and OX40L expression on CD11c
 
1
 
 dendritic cells (DCs)
in popliteal LNs of 
 
L
 
.
 
 major
 
–infected mice. These findings
substantiate a critical role of OX40–OX40L interaction in
the development of Th2 cells in vivo, possibly through T
cell–DC interaction in the draining LNs.
 
Materials and Methods
 
Animals and Antibodies.
 
Female BALB/c and C57BL/6 mice
were purchased from Charles River Japan, Inc. The animals were
6–7 wk old at the beginning of all experiments. Anti–mouse
OX40L (RM134L, rat IgG2b/
 
k
 
), anti–mouse CD70 (FR70, rat
IgG2b/
 
k
 
), and anti–mouse CD30L (RM153, rat IgG2b/
 
k
 
) mAbs
were prepared as previously described (15–17). Control rat IgG was
purchased from Sigma Chemical Co. An anti–mouse 4-1BBL
mAb was also generated in our laboratory (detailed characteriza-
tion of this mAb will be described elsewhere). In brief, an SD rat
was immunized with mouse B lymphoma 2PK-3 cells. The sple-
nocytes were fused with murine myeloma P3U1 cells as described
(18). After HAT selection, one hybridoma producing mAb TKS-1
(rat IgG2a/
 
k
 
) was identified by its strong reactivity with 4-1BBL–
transfected cells but not with mock-transfected cells. The TKS-1
mAb inhibited binding of soluble 4-1BB to and T cell costimula-
tory activity of mouse 4-1BBL transfectants in vitro.
 
Parasites and Infection of Mice. L
 
.
 
 major
 
 (MHOM/SU/73/5ASKH)
was provided by Drs. H. Ishikawa and K. Himeno (University of
Tokushima School of Medicine, Tokushima, Japan). Parasite in-
fectivity was maintained by in vivo passage in BALB/c mice. For
experimental infection, the parasites were collected from footpad
legions and expanded in Schnider’s medium (GIBCO BRL) sup-
plemented with 20% FCS at 25
 
8
 
C. Stationary phage promasti-
gotes were harvested, washed with PBS, and used for infection and
antigen preparation. Groups of six mice were infected with 5 
 
3
 
10
 
6
 
 promastigotes in the right hind footpad. In each group, mice
were injected intraperitoneally with 300 
 
m
 
g of anti-CD70, anti-
CD30L, anti–4-1BBL, or anti-OX40L mAb or control rat IgG at
the time of infection and subsequently twice per week until the
end of experiments. Progression of leishmaniasis was assessed by
weekly measuring of the swelling of the infected right footpad
compared with the uninfected left footpad. To prepare soluble
leishmanial antigens (SLAs) for ELISA, 10
 
9
 
 promastigotes were
subjected to three cycles of freezing and thawing and homoge-
nized. Protein concentration of SLA was determined using the
Bio-Rad Protein Assay reagent (Bio-Rad Labs.).
 
Flow Cytometric Analysis.
 
Popliteal LNs were digested with
collagenase (Wako Pure Chemical Industries, Ltd.), and cell suspen-
sion was collected and used for detection of OX40L on CD11b
 
1
 
 or
B220
 
1
 
 cells or OX40 on CD4
 
1
 
 T cells. To enrich DCs, low den-
sity cells were isolated by a BSA gradient (Sigma Chemical Co.) ac-
cording to the procedure described by Crowley et al. (19) and used
for detection of OX40L, CD70, 4-1BBL, or CD30L on CD11c
 
1
 
cells. Cell surface staining was performed as previously described
(15). In brief, 10
 
6
 
 cells were first preincubated with anti-CD16/32
mAb (FcBlock; PharMingen) and then incubated with biotiny-
lated control rat IgG, anti-OX40L (RM134L), anti-CD70 (FR70),
anti–4-1BBL (TKS-1), anti-CD30L (RM153), or anti-OX40 mAb
(MRC OX86) (reference 20). After washing with PBS, the cells
were incubated with FITC-labeled anti-CD11b, anti-B220, anti-
CD11c, or anti-CD4 mAb (PharMingen) and PE-labeled strepta-
vidin (PharMingen). After washing with PBS, the stained cells
(live-gated on the basis of forward and side scatter profiles and
propidium iodide exclusion) were analyzed on a FACScan™
(Becton Dickinson).
 
In Vitro Stimulation of CD4
 
1
 
 T Cells.
 
CD4
 
1
 
 T cells were pu-
rified from popliteal LNs at 50 d after the 
 
L
 
.
 
 major
 
 infection by
passage through a nylon fiber column (Wako Pure Chemical In-
dustries, Ltd.) and treatment with a mixture of hybridoma super-
natants (anti-MHC class II, M5/114; anti-CD8, 3.155; and anti-
B220, RA3-3A1) and low-tox rabbit complement (Cedarlane
Labs., Ltd.). CD4
 
1
 
 T cells (
 
.
 
95% pure) were pooled from three
mice in each group and stimulated with 50 ng/ml of PMA and
500 ng/ml of ionomycin (both from Sigma Chemical Co.) at 5 
 
3
 
10
 
5 
 
cells/ml in 96-well round-bottomed plates containing 200 
 
m
 
l
of RPMI 1640 medium supplemented with 10% FCS, 10 mM
Hepes, 2 mM 
 
l
 
-glutamine, 1 mM sodium pyruvate, 0.1 mg/ml
penicillin and streptomycin, and 50 
 
m
 
M 2-ME. For estimating
proliferative responses, the cultures were pulsed with 0.5 
 
m
 
Ci/
well of [
 
3
 
H]thymidine (DuPont-NEN) for the last 7 h. Incorpo-
rated radioactivity was measured as previously described (15). To
determine the production of cytokines, cell-free supernatants
were collected at 24–72 h and assayed for IL-2, IL-4, IL-5, IL-6,
IL-10, and IFN-
 
g
 
 by ELISA using OptEIA kits (PharMingen)
and IL-13 by using Quantikine mouse IL-13 kit (R & D Systems,
Inc.) according to the manufacturer’s instructions.
 
Measurement of Serum Ig by ELISA.
 
SLAs (10 
 
m
 
g/ml) were
coated onto 96-well CovaLink NH plates (Nunc, Inc.). After block-
ing with 1% BSA and 0.05% Tween 20 in PBS, 
 
L
 
.
 
 major
 
–specific
IgG isotypes were determined by incubating serially diluted se-
rum samples for 2 h at 37
 
8
 
C. After washing with 0.05% Tween
20 in PBS, wells were incubated with biotin-conjugated isotype-
specific mAbs, including anti–mouse IgG1 (Serotec) or anti–mouse
IgG2a, IgG2b, or IgG3 (PharMingen), washed, and then devel-
oped with Vectastain ABC kit (Vector Labs., Inc.) and 
 
o
 
-phenylen-
diamine (Wako Pure Chemical Industries, Ltd.). After terminat-
ing the reaction with 2N H
 
2
 
SO
 
4
 
, OD at 490/595 nm was
measured on a microplate reader (Bio-Rad Labs., Inc.). Total se-
rum IgG was quantitated by sandwich ELISA by using goat anti–
mouse IgG (Zymed Labs.) and biotin-conjugated anti–mouse
IgG (Vector Labs., Inc.) as described above. Total serum IgE was
quantitated by IgE-specific sandwich ELISA as previously de-
scribed (21).
 
Results
 
Effect of Anti-CD70, -CD30L, –4-1BBL, and -OX40L
mAbs on Murine Leishmaniasis.
 
To determine the contribu- 
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tion of CD70, CD30L, 4-1BBL, and OX40L to murine leish-
maniasis, susceptible BALB/c and resistant C57BL/6 mice
were administrated with neutralizing anti-CD70, -CD30L,
–4-1BBL, or -OX40L mAb or control rat IgG at the time
of 
 
L
 
.
 
 major
 
 infection and subsequently twice per week until
the end of experiments. As shown in Fig. 1, A and C, con-
trol IgG–treated BALB/c mice developed progressive le-
sions manifested by footpad swelling over a 50-d period af-
ter 
 
L
 
.
 
 major
 
 infection, whereas C57BL/6 mice treated with
control IgG developed only small lesions over that period
(Fig. 1, B and D). The administration of anti-OX40L mAb
markedly reduced the footpad swelling in susceptible BALB/c
mice (Fig. 1 A) but did not influence the resistance of
C57BL/6 mice (Fig. 1 B). In contrast, the administration of
anti-CD70, -CD30L, or –4-1BBL mAb exhibited no appar-
ent effect in either susceptible BALB/c or resistant C57BL/6
mice (Fig. 1, C and D). These results indicated that OX40L
plays a unique role in the development of susceptible phe-
notype in BALB/c mice but not in the development of re-
sistant phenotype in C57BL/6 mice.
 
Expression of OX40 and OX40L on Popliteal LN Cells from
L. major–infected BALB/c Mice.
 
Infection with 
 
L
 
.
 
 major
 
 in-
duces the expansion and differentiation of parasite-specific
CD4
 
1
 
 T cells that recognize 
 
L
 
.
 
 major
 
 antigens presented by
MHC class II molecules on the surfaces of DCs or mac-
rophages (M
 
f
 
) in the draining LNs (10, 22). To determine
whether CD4
 
1
 
 T cells express OX40 and DCs and/or M
 
f
 
express OX40L, we examined the expression of OX40 and
OX40L on popliteal LN cells from 
 
L
 
. major–infected
BALB/c mice. As shown in Fig. 2 A, OX40 was expressed
on a substantial part of CD41 T cells. On the other hand,
the expression of OX40L was found on CD11c1 DCs (Fig.
2 C) but not on CD11b1 Mf or B2201 B cells (Fig. 2 B).
CD11c1 DCs also expressed CD70 and CD30L but not
4-1BBL (Fig. 2 C). These results suggested that the adminis-
tration of anti-OX40L mAb ameliorated the leishmaniasis in
BALB/c mice, possibly by interrupting the OX40–OX40L-
mediated T cell–DC interaction in the draining LN.
Functional Phenotype of CD41 T Cells in Anti-OX40L–
treated BALB/c Mice. We next examined the functional
phenotype of CD41 T cells in the BALB/c mice that were
rendered resistant to L. major by treatment with anti-OX40L
mAb. CD41 T cells were isolated from the draining popliteal
LNs and stimulated with PMA and ionomycin, and then
proliferative response and cytokine production in the cul-
ture supernatants was assessed. As shown in Fig. 3 A, prolif-
erative responses of CD41 T cells were almost comparable
between the anti-OX40L–treated mice and the control
IgG–treated mice. However, the production of Th1 cyto-
kines IL-2 and IFN-g was slightly increased in the anti-
OX40L–treated mice as compared with the control IgG–
treated mice (Fig. 3, B and C). In contrast, the production
of Th2 cytokines IL-4, IL-10, and IL-13 was substantially
reduced in the anti-OX40L–treated mice as compared with
the control IgG–treated mice (Fig. 3, D–F). The mean sup-
pression of IL-4, IL-10, and IL-13 was 56.8 6 3.2% at 48 h,
Figure 1. Effect of anti-OX40L, -CD70, -CD30L, and –4-1BBL mAb
on the course of L. major infection. BALB/c mice (A and C) or C57BL/6
mice (B and D) were infected with 5 3 106 stationary phase promasti-
gotes subcutaneously in the hind footpad. Mice were treated with 300 mg
of anti-OX40L mAb (s, A and B), anti-CD70 (n), anti-CD30L (h), or
anti–4-1BBL (e) mAb (C and D) or control IgG (d, A–D) intraperito-
neally at the time of infection and subsequently twice per week until the
end of experiments. Net footpad swelling was measured by subtracting
the thickness of the uninfected footpad from that of the infected footpad.
Results are expressed as mean 6 SD of six mice in each group. Similar re-
sults were obtained in two independent experiments.
Figure 2. Expression of OX40
and OX40L on popliteal LN cells
from  L. major–infected BALB/c
mice at day 40 after infection. (A)
OX40 is expressed on CD41 T
cells. Popliteal LN cells proximal
to the footpad lesions of L. major–
infected BALB/c mice were
double stained with FITC-labeled
anti-CD4 mAb and biotinylated
anti-OX40 mAb or control IgG
followed by PE-labeled strep-
tavidin. (B) OX40L is not ex-
pressed on CD11b1 M f and
B2201 B cells. Popliteal LN cells
were double stained with FITC-
labeled anti-CD11b or anti-B220
mAb and biotinylated anti-OX40L
mAb or control IgG followed by
PE-labeled streptavidin. The his-
tograms show staining of electron-
ically gated CD11b1 or B2201
cells. Bold line shows staining
with anti-OX40L mAb, and
dotted line shows background
staining with control IgG. (C)
Expression of OX40L, CD70, 4-1BBL, and CD30L on CD11c1 DCs.
Low density cells from popliteal LNs were double stained with FITC-
labeled anti-CD11c mAb and biotinylated anti-OX40L, CD70, 4-1BBL,
or CD30L mAb or control IgG followed by PE-labeled streptavidin. The
histograms show staining of electronically gated CD11c1 cells. Bold line
shows staining with mAb against the indicated molecules, and dotted line
shows background staining with control IgG.378 Contribution of OX40 Ligand to Th2 Development In Vivo
39.2 6 3.4% at 72 h, and 53.0 6 4.9% at 72 h in three ex-
periments, respectively. Other Th2 cytokines, IL-5 and IL-6,
were also measured but not detectable in these experiments
(data not shown). These results indicated that anti-OX40L
mAb treatment suppressed the development of Th2 cells in
L. major–infected BALB/c mice.
Humoral Responses in Anti-OX40L–treated BALB/c Mice.
We also examined the total IgG, L. major–specific IgG, and
total IgE levels in the sera of infected mice. As shown in
Fig. 4 A, total IgG levels were slightly decreased in anti-
OX40L–treated mice as compared with control IgG–
treated mice, but the difference was not significant. In
contrast, levels of anti–L. major IgG1 were significantly re-
duced in anti-OX40L–treated mice as compared with con-
trol IgG–treated mice, whereas the levels of IgG2a, IgG2b,
and IgG3 were comparable (Fig. 4 B). Serum IgE levels in the
anti-OX40L–treated mice were also substantially reduced as
compared with those in the control IgG–treated mice (Fig.
4 C). These results are consistent with the reduced produc-
tion of IL-4 and IL-13, which promote IgG1 and IgE pro-
duction, by CD41 T cells shown in Fig. 3 and further sub-
stantiate that anti-OX40L mAb treatment suppressed the
Th2 development in L. major–infected BALB/c mice.
Discussion
Recently, it has been reported that OX40–OX40L-
mediated costimulation promotes the development of Th2
cells in vitro (8, 9). In this study, we found that the block-
ade of OX40L ameliorates progressive leishmaniasis in
BALB/c mice (Fig. 1 A). In vitro stimulation of CD41 T
cells from L. major–infected BALB/c mice showed that
anti-OX40L mAb treatment markedly reduced the pro-
duction of Th2 cytokines, including IL-4, IL-10, and IL-13,
as compared with control IgG treatment (Fig. 3). We also
observed that anti-OX40L mAb treatment substantially re-
duced anti–L. major IgG1 and serum IgE, which are pro-
moted by Th2 cells (Fig. 4). Taken together, these results
suggest that anti-OX40L mAb treatment ameliorated pro-
gressive leishmaniasis in BALB/c mice by suppressing Th2
development, substantiating a critical role of OX40–OX40L
in the development of Th2 cells in vivo. However, it
should be noted that the resistance conferred by anti-
OX40L treatment in L. major–infected BALB/c mice was
not permanent, and the disease progressed if treatment was
stopped at day 60 after the infection (data not shown).
Moreover, a short course of anti-OX40L treatment for 1 or
2 wk after the infection was not effective at preventing dis-
ease progression (data not shown). This seems to be due to
Figure 3. Functional phenotype of CD41 T cells in anti-OX40L–
treated BALB/c mice. CD41 T cells were purified from popliteal LNs of
L. major–infected BALB/c mice that were treated with anti-OX40L mAb
or control IgG 50 d after infection and stimulated with PMA and iono-
mycin for 24–72 h. (A) Proliferative response at 48 h was assessed by puls-
ing the cultures with 0.5 mCi/well of [3H]thymidine for the last 7 h. Pro-
duction of IL-2 (B), IFN-g (C), IL-4 (D), IL-10 (E), and IL-13 (F) in
culture supernatants at the indicated periods was measured by ELISA.
Results are expressed as mean 6 SD of triplicate cultures. Significant dif-
ferences between control IgG and anti-OX40L mAb treatment are indi-
cated by asterisks (*P , 0.05; **P , 0.01). Similar results were obtained
in three independent experiments.
Figure 4. Effect of anti-OX40L mAb
treatment on serum IgG Ab and IgE in
L. major–infected BALB/c mice. (A) Se-
rum total IgG 40 d after infection was
measured by sandwich ELISA. Results are
expressed as mean 6 SD of six mice in
each group. (B) L. major–specific IgG Ab
isotypes were determined with serum 40 d
after infection against SLAs by isotype-
specific ELISA. Data represent OD ob-
tained at a 500-fold dilution of serum and
are expressed as mean 6 SD of six mice in
each group. (C) Serum IgE at 14, 30, and
40 d after infection was measured by IgE-
specific sandwich ELISA. Results are expressed as mean 6 SD of six mice in each group. Significant differences between control IgG and anti-OX40L
mAb treatment are indicated by asterisks (*P , 0.05; **P , 0.01). Similar results were obtained in two independent experiments.379 Akiba et al. Brief Definitive Report
persistent infection of L. major in anti-OX40L–treated
BALB/c mice, which induces Th2 development persis-
tently. In fact, we observed a small number of parasites that
persisted in the infected footpads of the anti-OX40L–treated
mice even at day 60 after the infection (data not shown).
Therefore, anti-OX40L treatment did inhibit Th2 devel-
opment, but this did not necessarily result in a dramatic
shift to protective Th1 responses, as indicated by only
modest increase in IFN-g production (Fig. 3 C).
Some in vivo studies have demonstrated that CD28–
CD86-mediated costimulation may be critical for Th2 de-
velopment (2, 23). However, subsequent studies using
CD28-deficient BALB/c mice indicated that CD28 was
not an absolute requirement for Th2 development after
L. major infection (24). This also suggested that some com-
pensatory pathway may exist that promotes Th2 develop-
ment in the absence of CD28. In this respect, it is note-
worthy that the blockade of OX40L suppressed Th2
development in the presence of CD28 in L. major–infected
BALB/c mice. Moreover, we recently demonstrated that
OX40L can provide a CD28-independent costimulatory
signal to T cells (15). Therefore, the OX40–OX40L path-
way may play a dominant role over the CD28–CD86 path-
way toward promoting Th2 development in vivo.
In contrast to the unique effect of anti-OX40L mAb, the
administration of anti-CD70, anti-CD30L, or anti–4-1BBL
mAb exhibited no apparent effect in either susceptible
BALB/c or resistant C57BL/6 mice (Fig. 1). We confirmed
that rat IgG levels in the sera of mAb-treated mice were
maintained over 10 mg/ml during the whole course of the
experiments, which was sufficient to block T cell–costimu-
latory activity of each ligand in vitro (data not shown). This
suggests that the dose of mAbs was sufficient to block each
ligand in vivo. Our present results did not provide positive
evidence for a unique and essential role of CD70, CD30L,
and 4-1BBL in progressive leishmaniasis in BALB/c mice
or protection in C57BL/6 mice, but we could not exclude
the possible contribution of these molecules to the Th2 or
Th1 development in these mice. It remains possible that
these molecules or CD28/B7 may play a redundant role.
Further studies are now underway by using CD28-defi-
cient mice and combinations of anti-CD70, CD30L, and
4-1BBL mAbs.
It has been reported that L. major amastigotes, but not
promastigotes, efficiently entered DCs and increased the
expression of MHC class I and II, CD40, CD80, and CD86,
and IL-12 production, whereas infection of Mf with
amastigotes or promastigotes did not lead to changes in sur-
face antigen expression or cytokine production (25). Con-
sistently, we could not detect OX40L expression on CD11b1
Mf in popliteal LNs of L. major–infected BALB/c mice
(Fig. 2). We also could not detect OX40L on CD11b1 Mf
from peritoneal exudate cells when infected with promas-
tigotes in vitro or stimulated with LPS, IFN-g, anti-CD40,
or their combination (data not shown). Therefore, OX40L
appears not to be expressed on Mf under these conditions.
In contrast, we found OX40L expression on CD11c1 DCs
in popliteal LNs of L. major–infected BALB/c mice (Fig. 2).
It has been reported that OX40L was expressed on CD40-
stimulated human and mouse DCs (26, 27). We also ob-
served OX40L expression on CD40-stimulated CD11c1
DCs purified from normal mouse spleens (data not shown).
Therefore, the OX40–OX40L pathway may play an im-
portant role for Th2 development through T cell–DC rather
than T cell–Mf interaction. This notion is consistent with
the previous observation that the blockade of OX40L on
DCs inhibited Th2 development in vitro (8). It has re-
cently been shown that DCs contain two functionally dis-
tinct subsets that promote Th1 or Th2 development (28).
Further studies are now underway to characterize the pos-
sibly differential expression and function of OX40L on
these DC subpopulations.
Some recent studies indicated that the blockade of OX40–
OX40L interaction by administration of OX40–Ig amelio-
rated experimental allergic encephalomyelitis (EAE) and ex-
perimental colitis, which are Th1-mediated inflammatory
diseases (29, 30). We also observed that anti-OX40L mAb
treatment ameliorated actively induced or adoptive trans-
ferred EAE, which appeared to result from an antiinflamma-
tory effect of anti-OX40L mAb to inhibit the recruitment of
OX401 activated T cells to inflammatory sites rather than
the inhibition of Th1 development (Nohara, C., H. Akiba,
H. Yagita, and K. Okumura, manuscript in preparation). In
contrast, our present study demonstrated that the anti-
OX40L mAb treatment abrogated the progressive leishman-
iasis in susceptible BALB/c mice by selectively suppressing
Th2 responses, suggesting a critical role of OX40L in Th2
development in vivo. Therefore, an intervention in the
OX40–OX40L pathway of costimulation might be a novel
clinical strategy for the treatment of human leishmaniasis and
other Th2-associated diseases such as atopy and asthma.
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